Achmea Investment Management B.V. Sells 25,001 Shares of Intuitive Surgical, Inc. $ISRG

Achmea Investment Management B.V. cut its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 72.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,692 shares of the medical equipment provider’s stock after selling 25,001 shares during the quarter. Achmea Investment Management B.V.’s holdings in Intuitive Surgical were worth $4,335,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC raised its position in shares of Intuitive Surgical by 24.9% in the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock valued at $1,916,000 after purchasing an additional 731 shares during the period. Sivia Capital Partners LLC raised its holdings in Intuitive Surgical by 3.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock valued at $504,000 after acquiring an additional 34 shares during the period. Schnieders Capital Management LLC. lifted its position in shares of Intuitive Surgical by 38.0% during the second quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider’s stock worth $529,000 after acquiring an additional 268 shares in the last quarter. Westover Capital Advisors LLC purchased a new stake in shares of Intuitive Surgical during the second quarter worth $206,000. Finally, Empowered Funds LLC boosted its holdings in shares of Intuitive Surgical by 26.4% in the second quarter. Empowered Funds LLC now owns 11,793 shares of the medical equipment provider’s stock worth $6,408,000 after acquiring an additional 2,465 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

ISRG has been the topic of a number of analyst reports. Piper Sandler reiterated an “overweight” rating and set a $620.00 price objective (up from $610.00) on shares of Intuitive Surgical in a research note on Friday, January 23rd. The Goldman Sachs Group reaffirmed a “buy” rating and set a $714.00 target price on shares of Intuitive Surgical in a report on Friday, January 9th. Robert W. Baird decreased their price target on Intuitive Surgical from $655.00 to $645.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Royal Bank Of Canada increased their price target on shares of Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Finally, UBS Group cut their price target on shares of Intuitive Surgical from $570.00 to $550.00 and set a “neutral” rating for the company in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $614.95.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Company fundamentals and market positioning — Intuitive reported a strong January quarter (beats on revenue and EPS, ~19% revenue growth year‑over‑year) and is pursuing lower‑cost da Vinci systems to target fast‑growing ambulatory surgery centers, which could expand procedure volume outside hospitals over time. No external link
• Neutral Sentiment: Sector and competitive news with limited direct impact — other medtech product launches and approvals in the broader ecosystem (e.g., Merit Medical’s new esophageal stent) are being reported but do not directly displace Intuitive’s robotic surgery franchise. MMSI Launches Resilience TTS Stent for Esophageal Fistulas, Strictures
• Negative Sentiment: FDA regulatory flag — Intuitive was flagged by the FDA over a medical device issue, which raises near‑term regulatory and operational risk concerns; such notices can prompt customer caution, warranty/repair costs, or increased oversight that pressure sentiment. Intuitive Surgical flagged by FDA over medical device issue
• Negative Sentiment: Analyst outlook softened — UBS cut its price target from $570 to $550 and set a “neutral” rating, reducing near‑term upside expectations and likely contributing to selling pressure; the new target still implies some upside versus current levels but reflects more cautious sentiment. Intuitive Surgical (NASDAQ:ISRG) Price Target Lowered to $550.00 at UBS Group

Insider Buying and Selling

In other news, SVP Patricia L. Wadors sold 220 shares of Intuitive Surgical stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $499.71, for a total value of $109,936.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Mark Brosius sold 645 shares of the company’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $485.01, for a total transaction of $312,831.45. Following the completion of the transaction, the senior vice president owned 1,613 shares in the company, valued at approximately $782,321.13. The trade was a 28.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 32,943 shares of company stock valued at $17,279,568. 0.70% of the stock is owned by company insiders.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $477.73 on Thursday. The company’s 50 day moving average price is $507.10 and its 200-day moving average price is $512.85. Intuitive Surgical, Inc. has a 52-week low of $425.00 and a 52-week high of $603.88. The stock has a market capitalization of $169.66 billion, a price-to-earnings ratio of 60.55, a P/E/G ratio of 3.72 and a beta of 1.66.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The firm had revenue of $2.87 billion for the quarter, compared to analysts’ expectations of $2.72 billion. During the same period in the previous year, the firm earned $2.21 earnings per share. The business’s revenue was up 18.8% compared to the same quarter last year. As a group, equities research analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.